Effect of ciclosporin on safety, lymphocyte kinetics and left ventricular remodelling in acute myocardial infarction.
Suzanne CormackAshfaq MohammedPedram PanahiRajiv DasAlison J SteelThomas ChadwickAndrew BryantMohaned EgredKonstantinos StellosIoakim Spyridopoulosnull nullPublished in: British journal of clinical pharmacology (2020)
In our pilot trial, a single ciclosporin bolus did not affect infarct size or left ventricular remodelling, matching the results from CYCLE and CIRCUS. Our study suggests that ciclosporin does either not reach ischaemic cardiomyocytes, or requires earlier application during first medical contact. Finally, 1 bolus of ciclosporin is not sufficient to inhibit CD4 T-lymphocyte proliferation during remodelling. We therefore believe that further studies are warranted. (Evaluating the effectiveness of intravenous Ciclosporin on reducing reperfusion injury in pAtients undergoing PRImary percutaneous coronary intervention [CAPRI]; NCT02390674).
Keyphrases
- acute myocardial infarction
- left ventricular
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- patients undergoing
- st elevation myocardial infarction
- acute coronary syndrome
- coronary artery disease
- heart failure
- coronary artery bypass grafting
- randomized controlled trial
- hypertrophic cardiomyopathy
- antiplatelet therapy
- healthcare
- peripheral blood
- systematic review
- left atrial
- signaling pathway
- atrial fibrillation
- aortic stenosis
- low dose
- high dose
- ejection fraction